rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

Axogen, Inc.

AXGN · Nasdaq

Health CareMedical DevicesNot moving yet

AXGN stood above a rising 150-day average in 47 of the last 52 weekly readings, and has been out of that trend for the last 3 weeks. It is 16.2% below that average now. Medical Devices: 27% of its 181 stocks in an uptrend (−9 points in four weeks); Health Care: 25% (−11 points in four weeks).

Statistics

Rotation
Not moving yet
Weeks in an uptrend
out for 3
Industry in uptrend
27% -9 in 4 wk
Insider buys, 12 months
$0
Insider sales, 12 months
$25.8M
Officials’ trades on record
2
Institutions holding
239 (+32)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 47 of 52 weeks.

17 Apr – 16 Oct
19%29%40%Apr 26Jun 26Jul 26Sep 26Oct 26

Medical Devices: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026
−$10.2M$0Nov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

2 disclosed lines: House 2, Senate 0, executive 0; 1 people.

WhoDidAmountTraded
Donna E. Shalala House: U.S. House ClerkFL27sold$1k–$15k24 Jun 2019filed 27 Apr 2020
Donna E. Shalala House: U.S. House ClerkFL27bought$1k–$15k16 Apr 2019filed 27 Apr 2020

Insiders

Buy orders, 12 months0
Sale orders, 12 months32
Buyers · sellers0 · 12
WhoDidSharesTraded
Joseph A. TyndallDirectorsold3,500at $49.702 Sep 2026filed 4 Sep 2026
Amy McBride WendellDirectorsold13,353at $48.4211 Aug 2026filed 12 Aug 2026
Marc A. BeganEVP & General Counselsold67,500at $47.3510 Aug 2026filed 12 Aug 2026
Kathy Johnson WeilerDirectorsold14,150at $45.307 Aug 2026filed 11 Aug 2026
Amy McBride WendellDirectorsold1,647at $42.608 May 2026filed 12 May 2026
Doris QuackenbushSales VPsold3,878at $43.517 May 2026filed 8 May 2026
Lindsey Marie HartleyCFOsold478at $43.677 May 2026filed 8 May 2026
Lindsey Marie HartleyCFOsold573at $43.677 May 2026filed 8 May 2026
Jens KempChief Marketing Officersold4,000at $43.447 May 2026filed 8 May 2026
Kathy Johnson WeilerDirectorsold16,344at $44.097 May 2026filed 8 May 2026
John JohnsonDirectorsold11,050at $43.267 May 2026filed 8 May 2026
Erick Wayne DevinneyChief Innovation Officersold5,221at $32.8416 Mar 2026filed 18 Mar 2026

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders239+32 on the quarter
New · exited54 · 21
Reported value$2.3B

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
BlackRock, Inc.added · filed 7 Aug 20264,419,208$204.1M+548,357+14.2%
First Light Asset Management, LLCreduced · filed 14 Aug 20262,748,361$126.9M-1,254,407−31.3%
MORGAN STANLEYreduced · filed 13 Aug 20262,747,924$126.9M-375,058−12.0%
VANGUARD CAPITAL MANAGEMENT LLCreduced · filed 13 Aug 20262,257,948$104.3M-33,615−1.5%
Polar Capital Holdings Plcunchanged · filed 14 Aug 20261,500,822$69.3M00.0%
Artemis Investment Management LLPadded · filed 23 Jul 20261,396,792$64.5M+1,046,904+299.2%
WELLINGTON MANAGEMENT GROUP LLPadded · filed 14 Aug 20261,391,654$64.3M+427,089+44.3%
GEODE CAPITAL MANAGEMENT, LLCadded · filed 12 Aug 20261,375,240$63.5M+155,099+12.7%
CITADEL ADVISORS LLCadded · filed 14 Aug 20261,360,831$62.9M+1,115,777+455.3%
WASATCH ADVISORS LPreduced · filed 10 Jul 20261,295,949$59.9M-561,401−30.2%
31 Mar 2023 – 30 Jun 2026
112173234Mar 23Dec 23Dec 24Sep 25Jun 26

Everyone who traded it

Joseph A. Tyndall Company insiderDirector · last 2 Sep 20261 · 5
Amy McBride Wendell Company insiderDirector · last 11 Aug 20264 · 5
Marc A. Began Company insiderEVP & General Counsel · last 10 Aug 20260 · 3
Kathy Johnson Weiler Company insiderDirector · last 7 Aug 20260 · 4
Alan M. Levine Company insiderDirector · last 24 Jun 20260 · 1
John Johnson Company insiderDirector · last 24 Jun 20260 · 4
Paul Thomas Company insiderDirector · last 24 Jun 20260 · 1
William P. Mr. Burke Company insiderDirector · last 24 Jun 20261 · 11
Doris Quackenbush Company insiderSales VP · last 7 May 20260 · 1
Jens Kemp Company insiderChief Marketing Officer · last 7 May 20260 · 2
Lindsey Marie Hartley Company insiderCFO · last 7 May 20260 · 3
Erick Wayne DeVinney Company insiderChief Innovation Officer · last 16 Mar 20260 · 7

Same industry

RCEL Avita MedicalLeading+100%
ATRC AtriCureLeading+49%
HAE HaemoneticsLeading+48%
HTFL HeartflowLeading+40%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Profit per saleFY 2025 · to 31 Dec 202574.3%
Operating profit marginFY 2025 · to 31 Dec 2025-3.5%
Free cash flow marginFY 2025 · to 31 Dec 2025-1.3%
Return on capital employedFY 2025 · to 31 Dec 2025-4.0%
Debt to equityFY 2025 · to 31 Dec 20250.38×
Research spendFY 2025 · to 31 Dec 202514.6%
Share count trendFY 2025 · to 20 Feb 202610.0%
Cash and equivalentsFY 2025 · to 31 Dec 2025$35.5M
Free cash flowFY 2025 · to 31 Dec 2025−$2.9M

Analyst forecasts

No analyst forecasts yet.